Clinical Trial Update: A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib plus docetaxel versus docetaxel alone in advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: China Medical University, China | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN